Kevin Chartier

Kevin Chartier, as Principal Advisor of Biostatistics and Submissions Planning, Kevin works with the biostatistics team across MMS global operations to support Sponsors with complex studies, programs and submissions across various therapeutic areas and extending to rare diseases. In addition, he acts as the senior technical reviewer for complex biostatistics studies and advises Sponsors on both overall and quantitative specific methods and efficiencies at the protocol and project level, leading to health authority submissions.

Prior to MMS, Kevin has held positions at Astellas Pharma, Novartis, United BioSource Corporation, Wyeth, Pfizer, and Harris Laboratories. He completed his Ph.D. in Statistics from Kansas State University.

Suggested For You

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements